Edition:
United States

CEL-SCI Corp (CVM.A)

CVM.A on American Stock Exchange

0.09USD
26 May 2017
Change (% chg)

$0.00 (+1.76%)
Prev Close
$0.09
Open
$0.09
Day's High
$0.09
Day's Low
$0.08
Volume
142,887
Avg. Vol
295,240
52-wk High
$0.55
52-wk Low
$0.06

Latest Key Developments (Source: Significant Developments)

Cel-Sci Q2 loss per share $0.05
Wednesday, 10 May 2017 04:30pm EDT 

May 10 (Reuters) - Cel-Sci Corp ::Cel-Sci Corporation reports second quarter fiscal year 2017 financial results.Q2 loss per share $0.05.  Full Article

Cel-Sci announces $1.51 million registered direct offering
Monday, 1 May 2017 08:42am EDT 

May 1 (Reuters) - Cel-sci Corp :Cel-Sci announces $1.51 million registered direct offering.Cel-Sci - entered definitive agreement with one institutional investor for offering of shares of stock with proceeds of about $1.51 million in direct offering.Cel-Sci corp- intends to use net proceeds from offering for phase 3 clinical study and general corporate purposes.  Full Article

Cel-Sci gives update on partial clinical hold on phase 3 head and neck cancer study with multikine
Monday, 6 Mar 2017 08:00am EST 

Cel-sci Corp : Cel-Sci gives update on partial clinical hold on phase 3 head and neck cancer study with multikine . Cel-Sci - pursuant to partial clinical hold, patients currently receiving study treatments can continue to receive treatment at discretion of physicians . Cel-Sci - patients already enrolled in multikine drug study will continue to be followed . Cel-Sci-To provide updated investigator's brochure, procedures for compliance with requirements under 21 cfr 312 subpart d to address partial clinical hold . Cel-Sci - to provide to FDA list of major protocol deviations, which cel-sci believes will "affect study results" .Cel-Sci - to provide FDA a plan to identify major protocol deviations across all patients enrolled in phase 3 protocol for multikine drug.  Full Article

Cel-Sci says FDA issued incomplete response to hold letter to co
Thursday, 22 Dec 2016 04:53pm EST 

Cel-sci Corp : On December 16, FDA issued incomplete response to hold letter to co . Cel-Sci Corp - FDA's incomplete response to hold letter indicates co's Nov 18 submission is not complete response to all issues listed in FDA's clinical hold letter . Cel-Sci Corp- plans to send FDA a request for an in person meeting with agency to discuss all matters relating to partial clinical hold . Cel-Sci Corp- should FDA lift partial clinical hold remaining cost of phase 3 clinical trial will be higher than currently estimated . Cel-Sci Corp- reviewing all options in response to FDA's incomplete response to hold letter - sec filing .Cel-Sci Corp- estimate total remaining cash cost of phase 3 clinical trial, excluding any costs to be paid by partners, would be about $12.1 million.  Full Article

CEL-SCI submits response to FDA in connection with partial clinical hold on phase 3 clinical trial
Monday, 21 Nov 2016 08:30am EST 

Cel-sci Corp : CEL-SCI Corp - submitted response to FDA regarding partial clinical hold of CEL-SCI's phase 3 clinical trial of its investigational drug multikine .CEL-SCI submits response to fda in connection with partial clinical hold on phase 3 clinical trial.  Full Article

CEL-SCI reports clinical hold on head, neck cancer study
Monday, 26 Sep 2016 11:03pm EDT 

CEL-SCI Corp : Says CEL-SCI reports clinical hold on head and neck cancer study .CEL-SCI Corp says was also told to expect formal letter from FDA within 30 days and will work diligently with FDA to obtain release of clinical hold.  Full Article

CEL-SCI says arbitration hearing scheduled to begin on Sept 26 - sec filing
Friday, 2 Sep 2016 06:28am EDT 

CEL-SCI Corp : CEL-SCI arbitration hearing, brought by co against former CRO is scheduled to begin on Sept 26 - SEC filing Source: (http://bit.ly/2c9PUsU) Further company coverage: [CVM.A] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

Cel-Sci Q3 loss per share $0.03
Wednesday, 10 Aug 2016 08:00am EDT 

Cel-Sci Corp : Sci Corp reports third quarter fiscal year 2016 financial results .Q3 loss per share $0.03.  Full Article

Cel-Sci Corporation Q2 loss per share $0.07
Tuesday, 10 May 2016 04:40pm EDT 

Cel-Sci Corp : Cel-Sci corporation reports second quarter fiscal year 2016 financial results .Q2 loss per share $0.07.  Full Article

CEL-SCI Corp prices public offering for up to $12 mln
Friday, 23 Oct 2015 08:40am EDT 

CEL-SCI Corp:Prices public offering for up to $12 million.Says has priced a best efforts offering of common stock and warrants at a combined price of $0.67 per unit.  Full Article

More From Around the Web

BRIEF-Cel-Sci Q2 loss per share $0.05

* Cel-Sci Corporation reports second quarter fiscal year 2017 financial results